Therapeutic advances in leiomyosarcoma

Toward Personalized Treatment Approaches in Soft Tissue Sarcomas

Kelly: Chemotherapy remains the standard-of-care treatment for advanced soft-tissue sarcoma. However, objective response rates to doxorubicin- ...

Doxorubicin, standard first-line therapy for all sarcomas

A recent analysis by the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group retrospectively evaluated ...

Advances in Sarcoma: Focus on Clinical Trials - OHSU

– At least 2 prior lines of TKI therapy. Mike Heinrich [email protected]. Page 8. 8. Systemic Treatment of Advanced. Soft Tissue Sarcoma: Current Status. Page 9 ...

Treatment of advanced, metastatic soft tissue sarcoma - ResearchGate

PDF | Soft tissue sarcoma (STS) is a biologically heterogeneous malignancy with over 50 subtypes. Historically, there have been few systemic ...

Emerging Trends in Immunotherapy for Adult Sarcomas

Given quality-of-life concerns and the limited efficacy of chemotherapy in advanced soft-tissue sarcoma, there is a need for therapy regimens ...

1483O Results of a phase I/II combination regimen with ipilimumab ...

A 5-year phase I/II with an expanded phase II study of 101 patients has been recently reported. A subgroup of patients with advanced leiomyosarcoma (LMS) ...

First-Line Anlotinib Treatment for Soft-Tissue Sarcoma in ...

Purpose: Standard treatment for patients with unresectable locally advanced or metastatic soft-tissue sarcoma (LA/M STS) is chemotherapy based on anthracyclines ...

Efficacy and safety of anlotinib in advanced leiomyosarcoma | CMAR

Conclusion: Our results forecast that anlotinib is effective, safe and alternative in treatment of advanced leiomyosarcoma in real-world, ...

New therapeutics for soft tissue sarcomas - Frontiers

The limited durable response with traditional surgery, radiation, and chemotherapy in advanced-stage sarcoma has prompted research in novel ...

Sarcoma treatment in the era of molecular medicine - EMBO Press

Chemotherapy regimens of bone sarcomas (e.g., OS, EwS) combine doxorubicin, cisplatin, methotrexate, and ifosfamide administered before and/ ...

Pembrolizumab plus Pharmacologic Ascorbate in the Treatment of ...

Introduction: Leiomyosarcoma (LMS) is a malignancy with smooth muscle differentiation. Metastatic LMS is associated with poor prognosis and ...

Trabectedin and low-dose radiation therapy in patients with ...

In addition, four advanced and progressing leiomyosarcoma patients, all with extraordinarily long progression-free survival of over 18 months, were collected.

Advances of systemic treatment for adult soft-tissue sarcoma - Liu

In this review, we aim to summarize the advances of chemotherapy, targeted therapy and immunotherapy in the management of STS.

Gemcitabine and docetaxel versus doxorubicin as first-line treatment ...

For many years, first-line treatment for locally advanced or metastatic soft-tissue sarcoma has been doxorubicin. This study compared ...

Leiomyosarcoma Cancer: Causes, Symptoms, Treatment, & What it Is

Surgery. When surgery is possible, it's the best treatment option for leiomyosarcoma. · Chemotherapy. This treatment is often recommended when the tumor is large ...

Chemotherapy Regimens for Advanced Soft Tissue Sarcoma

There was a recent trial presented at ASCO this year looking at metastatic soft tissue, and the field had drifted with certain histologies ...

Funding Research on Targeted Therapies for Leiomyosarcoma

This research supports the further study of identified therapeutic targets in leiomyosarcoma in the hopes of taking one or more drugs to clinical trial.

Targeting the Molecular and Immunologic Features of ... - MDPI

Unfortunately, leiomyosarcoma does not seem sensitive to the first-generation immune-based therapies. In this review, we present the results of trials of ...

Sarcoma treatment | City of Hope

The primary treatment for early-stage or locally advanced sarcomas is surgical removal of cancerous tissue. The type of surgery varies depending on the type, ...

Use of first-line trabectedin in advanced leiomyosarcoma

Single-agent doxorubicin is the standard first-line therapy for advanced non-selected STS, although combination with ifosfamide appears to be superior in terms ...